Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.72 |
| ▸ | KIT | P10721 | 9/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | CDK9 | P50750 | 2/20 | 0.61 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745489 | 0.88 | CDK8 (0.69) | CDK8KITDYRK1ACCNT1CCNA2 | |
| SCHEMBL13745270 | 0.87 | CDK8 (0.71) | CDK8KITDYRK1A | |
| SCHEMBL15833785 | 0.87 | KIT (0.81) | CDK8KITDYRK1ACCNT1CCNA2 | |
| SCHEMBL8313358 | 0.86 | CDK8 (0.77) | CDK8KITDYRK1ACCNT1CCNA2 | |
| SCHEMBL8320052 | 0.86 | KIT (0.62) | CDK8KITDYRK1A | |
| SCHEMBL13745494 | 0.86 | KIT (0.71) | CDK8KITDYRK1ACCNT1CCNA2 | |
| SCHEMBL8321586 | 0.86 | CDK8 (0.80) | CDK8KITCCNT1CCNA2CDK2 | |
| SCHEMBL8313522 | 0.86 | KIT (0.78) | CDK8KITDYRK1APIK3CA | |
| SCHEMBL8320115 | 0.86 | CDK8 (0.84) | CDK8KITDYRK1ACCNT1CCNA2 | |
| SCHEMBL13753932 | 0.85 | CDK8 (0.58) | CDK8KITDYRK1ACCNT1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CDK8 360/4885KIT 3148/4885DYRK1A 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.